HP-main-image

Using Epigenetics for Cancer Detection in Liquid Biopsy

border

WHAT MAKES US UNIQUE

We developed EpiCheck to significantly improve cancer detection

Superior Results

We get better results by multiplexing own-developed methylation biomarker panels (15 for bladder cancer) and unique DNA methylation assay technology

Non Invasive

All our tests are based on small samples from body fluids like blood and urine, using basic lab instruments

Objective

Our test results are quantitative and unambiguous. For the same patient, every lab will get the exact same diagnosis

BLADDER EPICHECK®

15 biomarkers, strong performance*, available in EU in Q3 2016

Sensitivity

EpiCheck has a very high ability to correctly identify patients with cancer

Specificity

EpiCheck has a very high ability to correctly identify patients without cancer

NPV

EpiCheck negative predictive value result means 97% probability of being a true negative**

* Results are based on a clinical evaluation study with 222 bladder cancer patients post-treatment that came for recurrence monitoring. Performed in collaboration with Meir Medical Center, Israel

** Calculated assuming 17.6% prevalence of disease recurrence (as in this cohort)

Bladder EpiCheck is not cleared for clinical use. For research use only.

Our Mission

To improve patient treatment by providing better cancer monitoring and screening capabilities

OUR TECHNOLOGY PLATFORMS

Bringing significant innovation to cancer detection

setting

Throughout the years, our team developed very unique technological platforms that are used to develop products for detection of various types of cancers in simple-to-acquire body fluids like urine and blood. Our technology platforms include both a comprehensive method of creating non-overlapping biomarker panels for many cancer types, and a clinical assay that has a signal-to-noise ratio that is better than 1:150,000. These proprietary developments, in addition to others, result in very effective products that will change the cancer detection world.

NUCLEIX AT A GLANCE

dna

International expertise of diagnostic tests based on DNA methylation analysis

dna

Our employees: 75% Masters Degree and above, 30% MD or PhD

dna

Backed by OrbiMed and other leading investors

dna

Started R&D in 2008

dna

5 Patents submitted worldwide

dna

First Product-Bladder EpiCheck